On their own, selective targeting of these receptors also holds promise; increasing evidence points to the potential of treating MDD with 5HT2A agonists such as psilocybin, the active ingredient in ‘magic mushrooms’ [128]. The gene discussed is HTR2A; the disease is major depressive disorder.